NICE: A panacea for the NHS?: No, but it should be useful for managing the introduction of new technologies

BMJ

Volumn 318, Issue 7187, 1999, Pages 823-824

  Smith, Richard ^a  

^a BMJ ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; SILDENAFIL;

DRUG APPROVAL; EDITORIAL; GOVERNMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; MEDICAL AUDIT; MEDICAL TECHNOLOGY; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; RESOURCE MANAGEMENT; UNITED KINGDOM;

GREAT BRITAIN; STATE MEDICINE; TECHNOLOGY, MEDICAL;

EID: 0033608729     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.318.7187.823     Document Type: Editorial

References (8)

1. Thurber J. The years with Ross. London: Hamish Hamilton, 1984.
2. Chisholm J. Viagra: A botched case for rationing. BMJ 1999; 318: 273–274.
3. NHS Executive. Faster access to modern treatment: how NICE appraisal will work. In: Leeds: NHSE, 1999).
4. Coulson J. NICE work. (Interview with Sir Michael Rawlins.) BMA New Review 1999; 13 Mar:20–3.
5. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Potential benefits, limitations, and harms of clinical guidelines. BMJ 1999; 318: 527–530.
6. Senge PM. The leader's new work: building learning organizations. Sloan Management Review 1990; Fall: 7-23.
7. de Geus A. The living company. Harvard Business Review 1997; March-April: 51-9.
8. Senge PM. Leading learning organmizations. The bold, the powerful, and the invisible. In: The leader of the future. San Francisco: Jossey-Bass, 1996.